Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 13/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23637448 | 0.82 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL8049781 | 0.80 | FDPS (0.39) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL8050318 | 0.79 | FDPS (0.45) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Olpadronic Acid SCHEMBL138988 | 0.76 | FDPS (0.58) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL6664481 | 0.74 | FDPS (0.54) | FDPSGGPS1PDE3A | |
| Olpadronic Acid SCHEMBL232124 | 0.74 | FDPS (0.56) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL8050542 | 0.72 | FDPS (0.52) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL14947007 | 0.72 | FDPS (0.41) | FDPSGGPS1PDE3AALDH1A1 | |
| SCHEMBL12631211 | 0.71 | FDPS (0.49) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL132712 | 0.71 | FDPS (0.57) | FDPSGGPS1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0563096-B1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 2000-05-03 | — | — | EP | disclosed |
| US-5438048-A | Used for treatment of disorders related to metabolism of calcium and other bivalent metals; treats bone cancer, urolithiasis, rheumatoid arthritis, bone infection and bone degradation | LEIRAS OY (FI) | 1995-08-01 | — | — | US | disclosed |
| EP-0563096-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011267-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1992-07-09 | — | — | WO | disclosed |